Nebula Research & Development LLC Invests $4.10 Million in Becton, Dickinson and Company $BDX

Nebula Research & Development LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 23,802 shares of the medical instruments supplier’s stock, valued at approximately $4,100,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Saudi Central Bank acquired a new position in shares of Becton, Dickinson and Company during the first quarter worth about $26,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $31,000. Bell Investment Advisors Inc grew its stake in shares of Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 128 shares in the last quarter. WPG Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $36,000. Finally, Bank of Jackson Hole Trust boosted its holdings in Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 95 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Up 5.1%

BDX opened at $198.44 on Thursday. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The stock’s fifty day simple moving average is $188.58 and its 200 day simple moving average is $184.19. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The stock has a market cap of $56.64 billion, a PE ratio of 34.04, a price-to-earnings-growth ratio of 1.74 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 407 shares of company stock valued at $73,922. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BDX. Jefferies Financial Group increased their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Argus raised their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Royal Bank Of Canada cut their price objective on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a report on Friday, November 7th. Finally, Piper Sandler dropped their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $204.91.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.